Kiadis plots a Euro IPO; Amicus files Fabry drug for EU approval;

@FierceBiotech: Takeda uprooting its U.S. vaccines operations, joining the R&D migration to Boston. Report | Follow @FierceBiotech

@JohnCFierce: Trending: With a crucial CAR-T trial looming for Cellectis, a confident André Choulika is laying it all on the line. More | Follow @JohnCFierce

@DamianFierce: $FOLD plans to market the Fabry drug migalastat as Galafold. Release | Follow @DamianFierce

> Dutch biotech Kiadis Pharma is planning to go public on the Amsterdam and Brussels stock exchanges, raising cash for its pipeline of cancer treatments. News

> Amicus Therapeutics ($FOLD) has submitted migalastat, a treatment for the rare Fabry disease, for European approval. The company expects to file the drug with the FDA in the second half of the year. More (PDF)

> Cellectis ($CLLS) has recruited the cancer experts at Weill Cornell Medical College to accelerate the development of its lead CAR-T candidate for acute myelogenous leukemia. Release

> Merck ($MRK) has extended its collaboration with Agenus ($AGEN), working to develop new checkpoint inhibitors for cancer. Item

Medical Device News

@FierceMedDev: Merck teams up with NanoString to find genes that predict response to Keytruda. FierceDiagnostics article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Ishrak plays up four-point integration plan during Medtronic's earnings call. Story | Follow @VarunSaxena2

@EmilyWFierce: LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. FierceDiagnostics article | Follow @EmilyWFierce

> FDA clears first 'smart' spirometer, enabling continuous tracking of lung function via tablet. Story

> Former Stryker R&D exec spins off new company with novel bone adhesive. Report

> Aussie startup gets $11.5M to market FDA-cleared, wearable Parkinson's disease tracker. Article

Pharma News

@FiercePharma: India's pharmacies launch pre-emptive protest to online drug sales. FiercePharmaAsia article | Follow @FiercePharma

@EricPFierce: India's Wockhardt believes FDA issues at 2 key plants can be resolved sometime next year. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: It's Stanley Cup Finals day!! And I just slipped "power play" into a headline. | Follow @CarlyHFierce

> Roche unchallenged at top of cancer sellers, but Celgene could fight Novartis for No. 2. Story

> Endo plans $1.75B stock sale to help cover Par buy. Article

> Teva shops for bigger Mylan stake in deal-forcing power play. Report

Pharma Marketing News

> Eyeing Xofigo growth, Bayer launches 'speak up' campaign in prostate cancer. News

> Big Pharma grapples with idiosyncrasies of orphan drug marketing. Story

> Novo Nordisk spins cycling into diabetes awareness with pro racing team. Article

> GSK's Flonase zooms to top of allergy category after DTC push. Item

> High-profile Huntington's disease film scores on social media, but where was pharma? More

Biotech Research News

> NCI matchmaker study explores uses of targeted drugs. Item

> Circadian rhythm research spotlights a possible cancer drug target. Report

> Aging researchers at McMaster flag role of a key protein in muscle loss. More

> Regenerative med researchers advance work on recycling discarded kidneys. Article

> Northeastern team solves mystery of recurring Lyme disease, offers a solution. Story

Diagnostics News

> Roche's Ventana teams up with Halozyme for pancreatic cancer companion Dx. Story

> Invitae slashes prices for full menu of genetic tests. Item

> LabCorp strikes liquid biopsy deal with Sysmex for cancer drug development. Article

> Merck teams up with NanoString to find genes that predict response to Keytruda. Story

> France's Labco sells out to Cinven for $1.3B after abandoning IPO. Report